Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.14669
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma

Cancer Discovery
Oncology
2019English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor

International Journal of Basic & Clinical Pharmacology
2014English

Venetoclax as a Single Agent and in Combination With PI3K-MTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma

Lymphoma
2013English

Effects of the Proteasome Inhibitor Bortezomib in Combination With Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-Analysis

Turkish Journal of Haematology
Hematology
2019English

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone Prior to Combination With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Long-Term Outcomes and Mutation Profiling of Patients With Mantle Cell Lymphoma (MCL) Who Discontinued Ibrutinib

British Journal of Haematology
Hematology
2018English

Treatment of Resistant Mantle Cell Lymphoma With Allogeneic Bone Marrow Transplantation

Bone Marrow Transplantation
TransplantationHematology
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy